Treatment of restless legs syndrome by Polo, Olli
L Ä Ä K E I N F O R M A A T I O T A  L Ä Ä K E L A I T O K S E L T A
LÄKEMEDELSINFORMATION FRÅN LÄKEMEDELSVERKET, FINLAND  |  DRUG INFORMATION FROM THE NATIONAL AGENCY FOR MEDICINES, FINLAND 
4 . 2 0 0 1 TA
BU
LAK0104_I-IVkansilopu  31.8.2001  12:18  Sivu 3
S a m m a n d r a g
Ledare
Hannes Wahlroos  . . . . . . . . . . . . . . . . . . . . .
Olli Polo . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Om biverkningar
Erkki Palva . . . . . . . . . . . . . . . . . . . . . . . . . . .
Om medicintekniska produkter
Juha Nevalainen | Antti Pihakari  . . . . . . . . . .
S u m m a r y
Editorial
Hannes Wahlroos  . . . . . . . . . . . . . . . . . . . . .
Olli Polo . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ADR News
Erkki Palva . . . . . . . . . . . . . . . . . . . . . . . . . . .
Medical Devices
Juha Nevalainen | Antti Pihakari  . . . . . . . . . .
28
29
33
34
36
37
41
42
44
4.2001
9. vuosikerta
9 årgången
9th Annual volume
Läkemedel, pris och konkurrens
Behandling av syndromet restless legs
Statiner, myalgi och rabdomyolys i Finland
Register över tandimplantat
Medicines, prices and competition
Treatment of restless legs syndrome
Statins, myalgia and rhabdomyolysis in Finland
Register of dental implants
Lääkelaitoksen päätöksiä
LAK0104_03-04 sisältö  31.8.2001  12:23  Sivu 4
36 TABU 4.2001
Competition is one of the indispensable forces of market
economy. Public and social debates appear to favour
competition and shun regulations hampering free com-
petition. In Finland, there is legislation promoting fair
trading practices, and the Office of Free Competition
monitors compliance therewith. The fact that certain
functions in society neither can – nor were they ever in-
tended to – be based on the principle of free competi-
tion, gives rise to a conflict of interests. 
Health care services, including pharmaceutical ser-
vices are clear examples of such. In terms of our consti-
tution, the state shall promote the health of the inhabi-
tants, and ensure that equal social and health care ser-
vices are made available to all, as provided by law and
decree. In our specific health care legislation, including
the Medicines Act, provision is made for municipalities
to organise such services, and for the functions of phar-
macies. This legislation takes precedence over that relat-
ing to competition legislation. 
There are many reasons for restricted free competi-
tion of pharmaceutical services, thus creating a static
market. According economic theory, market conditions
are inadequate, if: 1) the goods, i.e. medicines, are not
being placed on the market freely, 2) the pricing of med-
icines is not free, 3) the number of service providers in
the market is limited, 4) the markets, i.e. consumers and
patients, do not have access to all relevant information
on medicines, their properties or prices, 5) entering or
leaving the market is controlled, 6) medicines are not
identical, and 7) instead of consumers, physicians decide
on what medicines are used, and furthermore, a major
proportion of the cost is borne by a third party, the so-
ciety. 
It is a fallacy to think that competitive pricing could
be introduced at pharmacy level under the current sys-
tem. If we want to have effective competition with price
in the pharmaceutical retail trade, we must first change
market conditions by reforming the relevant legislation.
Any serious debate on this aim has, however, not
emerged in recent years. 
Last spring, the Department of Social Services of the
Municipality of Helsinki decided to issue tenders for the
subsidised purchasing of medicines by its clients. For
obvious reasons, that decision had to be reviewed before
the end of June. Now that the municipal decision-mak-
ers are reconsidering the issue, they would do well to
think what means are appropriate for that sector of
health services. The principal means of competition are
simply not universally applicable.
The Medicines Act provides for fixed list prices of
medicines, which determine the sales margins of phar-
macies, and consequently the retail prices of medicines.
The purpose of imposing fixed list prices is that medi-
cines would be similarly priced at all pharmacies. The
tendency of some pharmacies to have reduced-price
sales shows that the idea behind the imposition of fixed
list prices has partially failed to be recognised. Should
legislators draw the conclusion that the sales margins of
pharmacies are unduly inflated, and take action to
counteract the trend? A draft bill to amend the Medi-
cines Act, drawn up at the Ministry of Social Affairs
and Health, has been circulated to interested parties,
and any comments on it are due this coming autumn. It
is more than reasonable to expect that the exact provi-
sions of the fixed list prices of medicines, as envisaged
when the current Act was enacted, will be based on
health politicy grounds. The patient needing medicines
should not be made to run from one pharmacy to an-
other in search of the daily special offer. 
Is any form of competition appropriate within the
pharmaceutical sector? Yes, indeed, and there are many
examples of this. From the society’s viewpoint, the most
beneficial form is the price competition between generic
medicinal products, provided that physicians’ prescrip-
tion practices could be influenced. Competition within
the pharmaceutical industry is also beneficial when it
leads to significant pharmaceutical innovations. Phar-
maceutical advertising and marketing also reflect the
competitiveness of the industry. In that regard, it is ob-
vious that physicians’ prescribing decisions, or con-
sumers’ decisions when buying self-care products, are
the objects of heavy competition. Although pharmacies
compete with each other, they are using means that are
suitable for the system. Those means include opening
hours, quality of services and the level of drug informa-
tion. 
It should be borne in mind that demand in the health
care market can grow indefinitely, but the payers’ re-
sources are limited. That makes regulation and control
necessary. We need a system ensuring the safe, equal,
and highly cost-effective provision of the health care
benefits referred to in the constitution. 
Hannes Wahlroos
DIRECTOR GENERAL
National Agency for Medicines 
Medicines, prices and competition
Editorial
Summary 
Translation Liisa Fellman-Paul
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Restless legs syndrome is a common
somatic disorder which is often tak-
en lightly by doctors.  By causing se-
vere sleep disturbance it can never-
theless impair the patient’s physical
and mental quality of life.  Recent
research results have shown that
there is no question of peripheral
neuropathy, a cramp or a psychiatric
disorder, but that the underlying
cause is a specific deficiency of CNS
dopaminergic neurotransmission
which can be reversed by drugs with
dopaminergic effect.
Diagnostic criteria
Restless legs syndrome was clearly
identified as early as in 1945 (1) but
internationally consistent clinical di-
agnostic criteria were not published
until a few years ago (2).
The diagnostic requirements for
the syndrome consist of four mini-
mum criteria which, when all are
fulfilled, allow the diagnosis of rest-
less legs syndrome to be made, and
six additional supportive criteria
(Table 1).
Typically, the patient tells of sen-
sations in the lower limbs which are
difficult to describe (paraesthesiae/
dysaesthesiae) and which are associ-
ated with the need to move the legs.
As the symptoms become more se-
vere, sensations may also be felt in
the upper limbs.  The patient uses
words such as stinging, tingling,
numbness, pain or ache. In addition
to the need to move the legs, the
sensation is associated also with mo-
tor restlessness (movement, rubbing,
shaking or cycling motion of the
legs, or walking). One of the diag-
nostic key features is that the sensa-
tions appear when the patient is mo-
tionless and they disappear again as
the patient starts moving.
The symptoms occur mostly in the
evening at bedtime and the patient
may find it difficult to fall asleep, or
at night after a couple of hours of
sleep, forcing the patient to get up
and walk.
Sleep disturbance and consequent
daytime fatigue are the most com-
mon reasons for seeing a doctor.
The patient is generally able to
associate motor restlessness with the
difficulty of falling asleep, but usual-
ly unable to explain why he or she
wakes up after a couple of hours of
sleep.  Stereotypical periodic move-
ments of limbs occur in over 80% of
the patients.
Idiopathic or secondary restless
legs?
In about half of the patients the
symptom is exhibited in an idiopath-
ic form without a precipitating fac-
tor or disease.  The idiopathic symp-
tom is generally inherited in an au-
tosomal dominant form, and the as-
sociated specific genetic abnormality
is still unidentified.  The secondary
form of the syndrome is mostly ex-
hibited in renal insufficiency,
anaemia associated with iron defi-
ciency and in rheumatism.  In about
11% of the pregnancies the syn-
drome occurs, usually after 20
weeks’ gestation. Restless legs syn-
drome may appear and sustain day-
time fatigue after the introduction of
CPAP treatment in patients with the
Olli Polo
PROFESSOR OF PHYSIOLOGY
University of Turku
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Ta b l e  1 .  D i a g n o s t i c  c r i t e r i a
Def init ive cr i ter ia
1. Sensations difficult for the patient to describe, occurring in the lower limbs and as-
sociated with the need to move
2. Motor restlessness (the patient needs to stretch or rub the muscles, toss and turn
and shift the legs in bed or get up and move about)
3. The symptoms only occur at rest (either lying down or sitting up) and are obvious-
ly relieved when the patient gets up to walk
4. Most of the symptoms occur in the evening and at night-time
Addit ional  cr i ter ia
1. Difficulties in falling asleep, or waking up at night, and daytime fatigue and ex-
haustion associated with sleep disturbance
2. Periodic limb movements reported by the patient
3. Periodic limb movements either during sleep (PLMS) or while drowsing off, re-
vealed by a sleep study 
4. Normal neurological findings
5. Typically progression of the clinical picture (a periodic discomfort becomes contin-
uous at first, the symptoms become more severe, and sensations  gradually come
to be felt also in the upper limbs)
6. Close relatives exhibiting the same symptoms (autosomal dominant inheritance)
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obstructive apnoea syndrome (3).
Antipsychotics that block dopamine
receptors may cause akathisia which
resembles restless legs syndrome.
Prevalence
With a prevalence of 5–10%, rest-
less legs syndrome is one of the most
common neurological diseases of the
adult population. There are signifi-
cant local and racial differences in
the prevalence of the inherited form.
Generally the symptoms are mild
and sporadic at first and the preva-
lence and severity increase with age.
Restless legs syndrome begins at
the age of 27 on average, even
though over 10% of the patients
have exhibited symptoms since
childhood.  In patients under the age
of 20, restless legs syndrome is often
misdiagnosed and thought to be
caused by rheumatism, hyperactivity
or psychological adjustment disorder.
Assessment of severity of 
restless legs syndrome
The symptoms of restless legs syn-
drome are generally mild and spo-
radic.  The disorder can be consid-
ered severe when symptoms occur
almost daily, they appear both in the
upper and the lower limbs, they are
associated with fatigue or exhaus-
tion which interferes with the day-
time activities, or when the patient
needs to make significant adjust-
ments in his or her way of living
and socialising due to the syndrome.
Fatigue and motor restlessness make
concentration on mental activities
difficult.  The need to move the legs
is most bothersome at the moment
when the patient is tired and would,
in fact, need a rest.
The most precise assessment of
the severity of the syndrome can be
made with the help of the 10-section
questionnaire designed by an inter-
national research group, where each
question is valued with points be-
tween 0 and 4.  The total amount
exceeds 20/40 points when the
symptoms are severe.
The intensity of night-time period-
ic movement of legs associated with
the syndrome can be defined by a
simple study using a static-charge-sen-
sitive bed (4). The degree of sleep dis-
turbance can be defined, for instance,
by measuring the quantity of leg
movements and associated arousals
using an electroencephalograph
(EEG).
Differential diagnosis
The diagnosis of the syndrome is
based on the patient’s history and is
generally confirmed when the four
main criteria are fulfilled.  The clini-
cal pictures of the idiopathic and the
secondary syndrome do not differ
from each other.  Problems of differ-
ential diagnosis generally occur in
patients with peripheral neuro-
pathies and who exhibit symptoms
of both at the same time.  A sleep
study may be necessary to exclude
alternative diagnoses of the syn-
drome. Table 2.
Treatment
Treatment of the syndrome (5,6)
aims at eliminating symptoms which
reduce the quality of life.  Treatment
is not likely to slow down, or for
that matter to speed up, the natural
progression of symptoms taking
place with age.  The syndrome is not
likely to be associated with in-
creased mortality, which the treat-
ment would otherwise aim to re-
duce.
After the diagnosis has been con-
firmed it is important to establish
Table 2.  Differential  diagnoses of restless legs syndrome
Diagnosis Differentiating features
Polynephropathy Paraesthesias and aches of the lower limbs which are not significantly alleviated by 
movement
Nerve root syndrome (sciatica) Lasègue and Kernig positive, may settle at rest
Cramp Painful muscle cramps which may also occur during the day.   May be provoked by 
exercise. 
Dyskinesias in the state of wakefulness Involuntary movements of limbs during wakefulness
Painful legs and moving toes A rare sequela following a spinal cord operation or damage, with involuntary painful 
movements
Burning feet syndrome Heat, not a typical symptom of restless legs syndrome
Arterial and venous disorders of Intermittent claudication syndrome or visible varicose veins of the lower limbs
the lower limbs
REM sleep behaviour disorder Violent movement during REM sleep which harms the patient or his/her sleeping partner
Narcolepsy Compulsive daytime seizures of falling asleep and cataplectic seizures 
Bruxism Wear and tear of teeth, hypertrophy of the masticatory muscle, reported by the sleep-
ing partner
Other forms of sleeplessness
Sleep-time respiratory disturbances Loud snoring and repeated interruptions of respiration  during sleep
(snoring and obstructive sleep apnoea)
Epileptic seizures Seizure-like motor symptoms, especially in children and adolescents
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whether it is a question of the idio-
pathic or the secondary form.   In
the first place, the use of and neces-
sity for drugs exposure to which
may cause the syndrome are exam-
ined.  Drug therapies harmful from
the point of view of the syndrome
are curtailed and as far as possible
withdrawn.  Underlying iron defi-
ciency can be checked by measuring
the serum ferritin concentration.
Levodopa
Unless it is possible to eliminate the
cause of the syndrome, drug therapy
should be considered.  Most of the
experience and placebo-controlled
research results are associated with
the combination therapy of levo-
dopa and peripheral dopadecar-
boxylase-inhibitor (7,8).  A dose of
100–200 mg of levodopa adminis-
tered one hour before bedtime will
reduce both idiopathic and sec-
ondary symptoms significantly, espe-
cially during the first half of the
night.  The effect can be prolonged
by making the evening dose  a com-
bination of 100–200 mg of levo-
dopa and 100–200 mg of the slow
release preparation of levodopa.
The initial dose should be as small
as possible (50–100 mg) and the
lowest effective dose is sought by
slowly increasing the dose.  Daily
doses in excess of 400 mg are not
recommended because the likeli-
hood of exacerbation of symptoms
and shift in the time of their occur-
rence will increase with high doses.
With the doses mentioned, levodopa
is generally well tolerated even with
long-term use.
Morning rebound, exacerbation
of symptoms or shifting of the time
of symptoms to evening or even
morning  may become  a problem
with levodopa therapy.  The likeli-
hood of these problems increases
with the use of high single doses.
Reduction in dose or a  gradual
change to slow release dopamine
agonists may solve the problem.
Dopamine agonists
Dopamine agonists include both the
conventional type with  ergotamine
structure such as bromocriptine,
pergolide and cabergoline and the
more recent types with non-ergota-
mine structure such as pramipexole
and ropinirole.  Studies with limited
patient material show some persua-
sive evidence of the effect of these
dopamine agonists in the treatment
of restless legs, but results of place-
bo-controlled studies are only avail-
able on pergolide and pramipexole
(Table 3).
Pergolide
Pergolide is an ergot alkaloid which
mainly stimulates the D1 and D2
dopamine receptor.  Patients who
develop exacerbation of symptoms
during levodopa therapy generally
obtain improved control of symp-
toms with pergolide (9,10). In the
placebo-controlled study (28 pa-
tients) the average dose of 0.5 mg
pergolide administered two hours
before bedtime prolonged the total
duration of sleep and reduced the
night-time periodic movements to
one tenth of the usual.  Subjectively
assessed quality of sleep and life and
symptoms of restless legs improved
significantly (11).
The most common adverse ef-
fects of pergolide include nausea,
vomiting and orthostatic hypoten-
sion.  To avoid adverse effects the
treatment should be started with
very low dose  (0.05 mg).  The dose
can be increased at intervals of a
couple of days until either adequate
response is obtained, or increase in
dose is prevented by adverse effects.
If adverse effects prevent the in-
crease in dose before the therapeutic
level is reached, treatment is contin-
ued with the highest tolerated dose
for some time.  After the patient has
become accustomed to the dose  it is
often possible to increase  it further.
Anti-emetic drugs with CNS effect
such as metoclopramide are not rec-
ommended because they have an an-
tagonistic influence on even the de-
sired effects of pergolide.
Table 3.  T h e  u s e  o f  d o p a m i n e  a g o n i s t s  i n  t h e  t r e a t m e n t  o f  r e s t l e s s  l e g s .
Pergol ide Pramipexole
Receptor affinity D1 and D2 6–8 times higher affinity for D3 receptor 
compared with D2 and D4 receptors
Introduction of treatment 0.05 mg 2–4 days 0.18 mg 1/2 tablet 2 days
0.10 mg 2–4 days 0.18 mg 1 tablet 2 days
0.20 mg 2–4 days etc. until therapeutic 0.18 mg 1 1/2 tablet 2 days etc. until 
dose is found (ad 0.75 mg) therapeutic dose is found (ad 0.36 mg)
Timing of dosage At night 1–2 hours before bedtime or prior At night 1/2 hour before bedtime or prior
to start of symptoms to start of symptoms
Typical therapeutic dose 0.12–0.5 mg 0.088–0.36 mg
End of treatment A quick decrease in dose may have a severe rebound effect  on the restless legs syn-
drome. To avoid this, treatment is withdrawn gradually by dividing the initial dose into 
halves
Most common adverse effects Nausea, vomiting, orthostatic hypotension Mild nausea
Rare adverse effects Drowsiness, swelling, white fingers, Drowsiness, sleeplessness, hallucinations,
erythema, pulmonary fibrosis compulsive tendency to fall asleep
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Pramipexole
Pramipexole is associated with con-
siderably fewer risks of adverse ef-
fects than pergolide.  It is likely that
it is precisely because of its D3 re-
ceptor selectivity that pramipexole is
both exceptionally effective in the
alleviation of restless legs symptoms
and well tolerated (12). Nausea,
dizziness, sleeplessness, constipation
and hallucinations have been report-
ed in patients with Parkinson’s dis-
ease who received significantly high
doses of pramipexole (maximum
dose of 3.3 g of alkali/day).  Para-
doxical increase in daytime fatigue
and tendency to fall asleep have also
been reported with high daily doses,
and consequently, the ability to dri-
ve, for instance, should be moni-
tored while the patient is becoming
accustomed to the treatment.
Due to its good tolerability,
pramipexole is easier to use than
pergolide, which is why it should be
considered as the primary choice
when long-term drug therapy is indi-
cated (Table 3).
Opioids
Opioids are effective drugs in the
treatment of restless legs syndrome,
but their use is restricted by the risk
of drug dependency and misuse. Due
to the minor risk of dependency and
misuse, tramadol 50–100 mg before
bedtime is in practice the only im-
portant alternative (13). Opioids
have traditionally been used in the
treatment of cases with severe symp-
toms and where levodopa resistance
occurs.  Due to the ease of use, tra-
madol could also in principle be
particularly appropriate in milder
cases where the drug could be taken
only as required to treat sporadic
symptoms.
Other drugs
Anti-inflammatory drugs and drugs
used for cramps are ineffective.  Pa-
tients with rheumatism and suffering
from restless legs syndrome, in par-
ticular, have an increased risk of
complications associated with gas-
trointestinal haemorrhages when
treating their leg symptoms them-
selves.
Treatment of restless legs in pri-
mary health care
Restless legs is a common, severely
underdiagnosed and largely untreat-
ed disorder which can reduce the
quality of sleep and life in a large
proportion of our elderly popula-
tion.  If hereditary, the symptoms
may start early, at a young age, and
interfere with cognitive functions
during schooling.  The secondary
type of restless legs syndrome is es-
pecially common in uraemia and
rheumatoid arthritis.
There are no generally approved
guidelines in Finland for the treat-
ment of restless legs syndrome.
Sending all patients for routine neu-
rological examinations and treat-
ment would not be sensible because
the syndrome is so common.  My
suggestion is that a general practi-
tioner familiar with the treatment of
restless legs could treat the primary
or secondary syndrome when the
neurological findings are normal,
the age of the patient is over 30
years, and the symptom responds
well to a small dose of dopamine ag-
onist.  A consultation with a neurol-
ogist is perhaps appropriate when
the symptoms are unusual, there is
total absence of or only partial re-
sponse to treatment, relatively high
therapeutic doses are required, or
exacerbation of symptoms develops
during treatment.
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Summary 
Right in the beginning of the clinical
use of  the statins it was known that
in rare cases they may cause muscu-
lar pain, myopathy and even rhab-
domyolysis. It has been suspected
that this adverse effect may, at least
partly, be associated with ubiqui-
none deficiency, due to the decrease
of ubiquinone-transporting LDL by
the statin treatment. Estimates about
the incidence of myopathy vary
much: depending on the patient se-
lection, medicine, dose and diagnos-
tic criteria the estimates range from
1:2000 or 1:3000 to 1:10 000 treat-
ment year. Of other lipid lowering
drugs the fibrates cause similar mus-
cle disorders, and concurrent use of
fibrates and statins includes a high
risk of these adverse effects. 
The adverse drug reactions -reg-
ister in Finland has since 1988 re-
ceived 62 reports of myalgia, in-
crease in creatinine kinase or rhab-
domyolysis (table). The share of
muscular disorders of all adverse re-
actions reported of each statin
ranges from 20 % to 43 %, indicat-
ing that there are no significant dif-
ferences among the individual drugs.
Due to the small use and few reports
it is too early to state anything
about cerivastatin yet. 
There are four cases of rhab-
domyolysis in connection with the
statin treatment:
Patient 1 is a 54 years old
woman who had lovastatin 80
mg/day for the treatment of hyper-
cholesterolemia. The patient started
itraconazol 200 mg/day for nail fun-
gal infection, and two weeks later
she experienced muscular pains, fa-
tigue and her urine turned dark.
Serum creatinine kinase was 18 770
U/L at the highest. 
Patient 2 is a 66 years old
woman who received pravastatine
20 mg/day in addition to the previ-
ous treatment with bezafibrate 800
mg/day. After months of this con-
comitant medication fatigue and
pain in lower limbs began. Serum
creatinine kinase was 10 240 U/L.
Patient 3 is a 52 years old man
who previously had had ciclosporine
for the treatment of membraneous
glomerulonephritis. Simvastatine 80
mg/day was used for hypercholes-
terolemia. Ciclosporine was started
again, and within one month muscu-
lar pains and weakness developed.
Serum creatinine kinase was 196 000
U/L.
Patient 4 is a 51 years old
woman with diabetes who received
simvastatine 80mg/day. Within a
month she had muscular pains in
her legs. Serum creatinine kinase
was 57 000 U/L.
The importance of interactions is
stressed by the fact that in the above
mentioned cases, only in one case
statin treatment alone was related to
rhabdomyolysis. In the first case the
interaction was pharmacokinetic:
itraconazole increased the level of
lovastatin by preventing its metabo-
lism. Bezafibrate may cause similar
harmful muscular adverse effects
than statins. In the third case multi-
ple mechanisms may be involved: re-
nal insufficiency alone can predis-
pose for rhabdomyolysis caused by
lipid lowering drugs, and ciclospor-
ine can increase the level of simvas-
tatine. 
The statins, myalgia and rhabdomyolysis in Finland 
Erkki Palva
PROFESSOR, RESEARCH DIRECTOR
Drug Information Centre
National Agency for Medicines
D r u g Reports Myalgia/CK increase Rhabdomyolysis
Simvastatine 38 11 2
Lovastatine 57 20 1
Pravastatine 5 1 1
Fluvastatine 42 18 0
Atorvastatine 41 8 0
Serivastatine 3 0 0
A D R  N e w s
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The creation and development of the
Finnish dental implant register are in
many respects linked to the endo-
prosthesis register started by the
Finnish Orthopaedist Association in
1980.  The administrative develop-
ment of the register has evolved
from a register held by the Ortho-
paedist Association, via the National
Board of Health and the National
Research and Development Centre
for Welfare and Health, ultimately
into a national register held by the
Medical Devices Centre of the Na-
tional Agency for Medicines.  The
implants register was extended on 1
April 1994 to include also collection
of data on  dental implants installed
and removed in the country.  The
need for a further extension of the
implants register has been discussed
but no final conclusion has yet been
reached.  Artificial materials are in-
creasingly being used  in replacing
the functions of organs, and not all
their effects are known.  For this
extensive monitoring to safeguard
patient safety would be necessary.
After long-term pioneering work,
implant studies were further devel-
oped especially by Professor Bråne-
mark, who installed the first dental
implants in Sweden in the beginning
of the 1970s.  The first dental im-
plants in Finland were installed in
Turku and Helsinki in 1981.  The
development world-wide has been
very rapid and new innovations are
constantly emerging in the areas of
both methods and materials.  Over
200 brand names of dental implants
are already in use in the world, and
the brand names cover a large range
of various types of products.  About
20 brand names are in use in Fin-
land at present, the three most com-
mon of which cover about 75% of
the market.
The reasons for setting up a den-
tal implant register were largely the
same as those for registering endo-
prostheses.  It is a question of a den-
tal care method which will rapidly-
come into common  use and which
is associated with complex new
techniques as regards both  materi-
als and product development.  The
users of dental implants are required
to have quantities of new informa-
tion about oral surgery, roentgenolo-
gy, and prosthetics as well as paro-
dontology.  New laboratory tech-
niques are also involved in the den-
tal technical work.  The most im-
portant and difficult task, however,
is the correct selection of patients
for whom the new, relatively costly,
and also difficult, method is appro-
priate.  It should be possible to as-
sess the total risks involved with the
method so that the patient is able to
take advantage of and fully compre-
hend the information in question
and capable of correct occlusion
which is even financially valuable.
Above all, it is a question of patient
safety which is aimed at improving
the patient’s well-being and quality
of life.
Research results for each brand
name may not necessarily be gener-
ally applicable in a situation where
the implants are becoming more
widely used and involving the entire
medical profession, in which case
the group of prescribers will be less
homogenous.  Only extensive, con-
tinuous monitoring will reveal the
rare risk situations, patient injuries
and product defects which will have
consequences for patient safety and
which may elude the experience and
knowledge of an individual pre-
scriber throughout his or her entire
professional career.  The register is
intended to provide the users  with
up-to-date information on the
progress of dental implants and the
success of treatment.  A dental im-
plant should retain its good func-
tional properties for several decades.
Even today, a 100% success rate is
not possible with implants.  A risk
of failure is possible under many cir-
cumstances.
The dental implant register today
contains data on 50,000 installed
implants.   This is the first nation-
wide registered file in the world.
The  material contained in it is ex-
ceptionally extensive.  There are, in
fact, several large filing projects also
under development in other coun-
tries. The Danish national file is
probably likely to be completed
next.  The Finnish National Agency
for Medicines has had the opportu-
nity to elaborate on the problems in-
volved in the collection and process-
ing of registered data, and the
Agency has played a part in helping
other national registers to be set up.
A Nordic register has good
prospects of success.  The training
of the medical profession is very
similar and patients are well within
the reach of the Nordic health care
system.  Change of domicile  by pa-
tients is relatively infrequent, and
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each individual is identifiable in the
health care register.  Very few coun-
tries have similar possibilities.
The use of dental implants has
increased.  In 1995 the register con-
tained data on 3,000 implants and
in 2000 it already included data on
almost 10,000 implants involving
about 5,000 operations.  The brand
names of dental implants most com-
monly used in Finland are ITI
(Straumann), Astra and Bio Care
(Brånemark).  There are two or
three Finnish manufacturers, and the
number of brand names totals 20.
The brand names of dental implants
have been retained on the Finnish
market for a relatively long period
of time, but one should be prepared
for changes as development of each
brand name proceeds and the struc-
ture of various components is con-
stantly changing.
According to the register, about
800 dental implants have been lost
within six years of use; this accounts
for 2% of all installed implants.
Various publications have reported
2–7% losses after 5–10 years of use.
These reports are difficult to com-
pare directly with the data of the
National Agency for Medicines be-
cause of the different circumstances
that prevailed and the different ways
of collecting the data.  A careful as-
sessment would conclude that the
success rate of results in Finland is
very comparable to that of other
countries.  The percentage of fail-
ures and complications appears to
have decreased  during recent years,
which is probably a sign of im-
proved expertise.  Not only front
teeth but all types of teeth have been
replaced with dental implants.  The
installation of implants in the elderly
has increased.
Last year, dental implants were
installed at about 300 different den-
tal surgeries or hospitals.  Only
about 10% of the dental implants
were installed in the public health
sector, and about half of them even
in hospital.  In practice, the installa-
tion of implants is to a large extent
concentrated  in private dental surg-
eries.  The number of implant in-
stallers was 160.  Only 20 of them
carried out more then 50 dental im-
plant operations a year, and 50 of
them less than 5 operations a year;
this can be considered as insufficient
for the maintenance of  professional
skills.  Several extensive studies have
shown that the first nine operations
are associated with complications
distinctly more frequently than sub-
sequent operations.  In the near fu-
ture, serious discussion is likely to
become necessary to establish the
number of operations required to
produce sufficient experience and
skills to use dental implants.  Dis-
cussion is also likely to be needed to
establish who should be members of
a dental implant working group in
order to fulfil the necessary quality
criteria.
Judging from the sales figures of
dental implants, not all those carry-
ing out implant operations have re-
membered to report them to the reg-
ister.  Consequently, the dental im-
plant register does not cover all im-
plants installed in the country.
It would be of vital importance
for the register that information as
up-to-date as possible  should be
collected on all implant operations.
The register is in principle only as
good as the reports contained in it.
An English publication of the data of the
dental implant register prepared by the
National Agency for Medicines on the
dental implants installed and used in
Finland during 1994–2000 is available
on the Internet at website www.nam.fi/ ;
it is called the 2000 Dental Implant
Yearbook. 
Translation  Mervi Moisander
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